Premium Nahrungsergänzungsmittel | artgerecht

Fedratinib: JAK2 Inhibitor for Myelofibrosis

Fedratinib is a targeted medication used to treat myelofibrosis, a rare bone marrow disorder. It selectively inhibits the enzyme JAK2, reducing spleen enlargement and relieving disease-related symptoms.

Regular tips about health Regular tips about health

Things worth knowing about "Fedratinib"

Fedratinib is a targeted medication used to treat myelofibrosis, a rare bone marrow disorder. It selectively inhibits the enzyme JAK2, reducing spleen enlargement and relieving disease-related symptoms.

What is Fedratinib?

Fedratinib is a targeted cancer therapy belonging to the class of JAK2 inhibitors (Janus kinase 2 inhibitors). It is designed to treat specific blood-forming disorders in which the enzyme JAK2 is abnormally overactive. Fedratinib is approved in the United States and the European Union under the brand name Inrebic.

Indications

Fedratinib is approved for the treatment of adults with:

Myelofibrosis (MF) – a rare, chronic bone marrow disorder in which normal marrow tissue is progressively replaced by scar tissue (fibrosis)
Primary myelofibrosis as well as secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia
Patients who have been previously treated with the JAK inhibitor ruxolitinib or who are ineligible for it

Mechanism of Action

Fedratinib works by selectively inhibiting the enzyme JAK2 (Janus Kinase 2), a signaling protein that transmits growth signals within cells. In myelofibrosis, JAK2 is pathologically overactivated – most commonly due to a genetic alteration known as the JAK2-V617F mutation.

By blocking JAK2, fedratinib suppresses the JAK-STAT signaling pathway, which drives the uncontrolled proliferation and survival of abnormal blood cells. This leads to a reduction in splenomegaly (enlarged spleen) and improvement of systemic symptoms such as night sweats, fatigue, and unintentional weight loss.

In addition, fedratinib also inhibits the FLT3 receptor (FMS-like tyrosine kinase 3), which may contribute to its efficacy in patients who have developed resistance to other JAK inhibitors.

Dosage and Administration

Fedratinib is available as oral capsules. The recommended standard dose is 400 mg once daily, taken with food to improve tolerability and reduce nausea.

Treatment is continued as long as the patient benefits and side effects remain manageable.
Dose adjustments may be required in patients with renal impairment or when used alongside drugs that interact with the metabolic enzyme CYP3A4.
Treatment should always be initiated and monitored by a specialist physician.

Side Effects

Like all cancer medications, fedratinib may cause side effects. Common side effects include:

Nausea and vomiting (very common, especially at the start of treatment)
Diarrhea
Anemia (low red blood cell count)
Thrombocytopenia (low platelet count)
Elevated liver enzyme levels
Fatigue and weakness

A rare but serious risk is Wernicke encephalopathy – a brain disorder caused by severe thiamine (Vitamin B1) deficiency. Patients must have their thiamine levels checked before and during treatment. Symptoms such as confusion, loss of coordination, or vision disturbances require immediate medical attention.

Drug Interactions

Fedratinib is primarily metabolized by the liver enzyme CYP3A4. The following interactions are clinically relevant:

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase fedratinib blood levels and the risk of adverse effects.
Strong CYP3A4 inducers (e.g., rifampicin, St. John's Wort) reduce fedratinib levels, potentially decreasing its effectiveness.
Concurrent use with other agents that suppress bone marrow function should be avoided or carefully monitored.

Contraindications

Known hypersensitivity to fedratinib or any excipient in the formulation
Severe hepatic impairment
Pregnancy and breastfeeding (fedratinib may harm the unborn child)
Pre-existing or current thiamine deficiency without adequate supplementation

References

European Medicines Agency (EMA): Inrebic (fedratinib) – European Public Assessment Report (EPAR), 2021. Available at: www.ema.europa.eu
Harrison CN et al. – Fedratinib in myelofibrosis previously treated with ruxolitinib: JAKARTA-2 study results. Annals of Hematology, 2020.
U.S. Food and Drug Administration (FDA): Inrebic (fedratinib) Prescribing Information. Silver Spring, MD: FDA, 2019. Available at: www.fda.gov

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.